Cardiovascular disease and mortality sequelae of COVID- 19 in the UK Biobank, 2022, Raisi-Estabragh et al.

Discussion in 'Long Covid research' started by Cheshire, Oct 26, 2022.

  1. Cheshire

    Cheshire Moderator Staff Member

    Messages:
    4,675
    ABSTRACT

    Objective
    To examine association of COVID-19 with incident cardiovascular events in 17 871 UK Biobank cases between March 2020 and 2021.

    Methods
    COVID-19 cases were defined using health record linkage. Each case was propensity score-matched to two uninfected controls on age, sex, deprivation, body mass index, ethnicity, diabetes, prevalent ischaemic heart disease (IHD), smoking, hypertension and high cholesterol. We included the following incident outcomes: myocardial infarction, stroke, heart failure, atrial fibrillation, venous thromboembolism (VTE), pericarditis, all-cause death, cardiovascular death, IHD death. Cox proportional hazards regression was used to estimate associations of COVID-19 with each outcome over an average of 141 days (range 32–395) of prospective follow-up.

    Results
    Non- hospitalised cases (n=14 304) had increased risk of incident VTE (HR 2.74 (95% CI 1.38 to 5.45), p=0.004) and death (HR 10.23 (95% CI 7.63 to 13.70), p<0.0001). Individuals with primary COVID-19 hospitalisation (n=2701) had increased risk of all outcomes considered. The largest effect sizes were with VTE (HR 27.6 (95% CI 14.5 to 52.3); p<0.0001), heart failure (HR 21.6 (95% CI 10.9 to 42.9); p<0.0001) and stroke (HR 17.5 (95% CI 5.26 to 57.9); p<0.0001).
    Those hospitalised with COVID-19 as a secondary diagnosis (n=866) had similarly increased cardiovascular risk. The associated risks were greatest in the first 30 days after infection but remained higher than controls even after this period.

    Conclusions
    Individuals hospitalised with COVID- 19 have increased risk of incident cardiovascular events across a range of disease and mortality outcomes. The risk of most events is highest in the early postinfection period. Individuals not requiring hospitalisation have increased risk of VTE, but not of other cardiovascular- specific outcomes.

    https://heart.bmj.com/content/heartjnl/early/2022/09/21/heartjnl-2022-321492.full.pdf

    CNBC article about this study
     
    Last edited: Oct 26, 2022
  2. cassava7

    cassava7 Senior Member (Voting Rights)

    Messages:
    1,051
    Only one word comes to mind: yikes.
     
  3. RedFox

    RedFox Senior Member (Voting Rights)

    Messages:
    1,297
    Location:
    Pennsylvania
    27.6 is among the highest hazard ratios I've ever seen in a scientific paper.
     
    Peter Trewhitt, Mij and Binkie4 like this.
  4. CRG

    CRG Senior Member (Voting Rights)

    Messages:
    1,860
    Location:
    UK
    Worth noting that the median age of the patient cohort is 65 (58 - 73) - see row three, Table 1. Confirming that COVID19 is a cause of significant morbidity in older people, but doesn't necessarily tell us anything about COVID19 infection in younger people.
     
    RedFox, alktipping, ukxmrv and 3 others like this.
  5. Sean

    Sean Moderator Staff Member

    Messages:
    8,154
    Location:
    Australia
    Yet another reason for late-50s me to avoid getting Covid. :bag:
     
  6. Binkie4

    Binkie4 Senior Member (Voting Rights)

    Messages:
    2,604
    I wonder if paxlovid and molnupiravir have any effect on improving these outcomes. I haven't read much about their effects.
     
    RedFox, Peter Trewhitt and Trish like this.
  7. Cheshire

    Cheshire Moderator Staff Member

    Messages:
    4,675
    Even a mild case of COVID can put you at higher risk for blood clots and death, according to a new study
    Erin Prater

    Article in Fortune
     
    Binkie4, RedFox, Trish and 1 other person like this.

Share This Page